A New Vaccine Against Depression? | MYND Life Sciences
While many psychedelics companies are developing treatments for depression, MYND Life Sciences hopes to prevent depression from developing in the first place.
MYND recently signed a licensing agreement with Eyam, a private vaccine developer, to create a vaccine that would prevent neurological disorders including depression. The underlying theory is that depression is essentially neuro-inflammation, and psychedelics may have an anti-inflammatory effect that could prevent the neuro-inflammatory process.